2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 502

Implications of Coronary Artery Calcium Score and Its Change over Time As Markers of Coronary Plaque Vulnerability and Patient Risk in Rheumatoid Arthritis
Abstract Number: PP09

Improved Quality of Life and Decreased Symptoms of Lupus with Diet, Exercise, and Functional Medicine
Abstract Number: PP04

Improved Quality of Life with Patient Engagement in Research
Abstract Number: 592

Improved Response to Etanercept Is Associated with Serum Vitamin D Levels in Rheumatoid Arthritis
Abstract Number: 245

Improvement in Fibromyalgia Symptoms and Skin Biopsy Results in Patients with Fibromyalgia and Small Fiber Neuropathy Treated with Intravenous Immune Globulin Infusion( IVIG)
Abstract Number: 1644

Improvement in Morning Stiffness in Subjects with Psa Is Associated with Improvements in Pain, Physical Function, and Patient Global Response to Treatment
Abstract Number: 1654

Improvement of Cytological Grade and Tear Production in Ankylosing Spondylitis Patients Under Anti-TNF Therapy: A Long-Term Follow-up
Abstract Number: 1550

Improvement of HbA1c in Patients with Rheumatoid Arthritis and Diabetes Type 2 during Treatment with Tocilizumab
Abstract Number: 1843

Improving Access to Rheumatology Care for High-Risk Lupus Patients Can Help Decrease Hospitalizations
Abstract Number: 197

Improving Clinical Decisions for Gout Management: Effect of Online Case-Based Education
Abstract Number: 2963

Improving Clinically Inactive Disease in Patients with Juvenile Idiopathic Arthritis- a Quaternary Center Experience
Abstract Number: 2294

Improving EULAR/Acr Classification Criteria for Idiopathic Inflammatory Myopathies
Abstract Number: 466

Improving Pneumococcal Vaccination Rates in Childhood-Onset SLE Patients at a Large Tertiary Care Center: The Path to Creating a More Sustainable Model of Vaccination with the Help of EMR
Abstract Number: 349

Improving the Performance of the Spanish Version of QOL-RA
Abstract Number: 54

In a Macaque Model of RA By Immunization with Citrullinated Peptides, the Valine in the 11 Position of the DRB1 Molecule Has Greater Impacts on T-Cell Response to Citrullinated Peptides Than the 70-74 Position in the Shared Epitope

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].